Navigation Links
Proove CEO and Vice Chairman of the Howard County Board of Education, Brian Meshkin, Selected as one of Howard County's Finest Under 39 by the Cystic Fibrosis Foundation
Date:9/24/2013

Irvine, CA (PRWEB) September 24, 2013

Proove Biosciences Inc., the leading personalized pain medicine laboratory, is proud to announce CEO Brian Meshkin has been selected as one of Howard County’s Finest Under 39. Meshkin is also the Vice Chairman of the Howard County Board of Education, and an avid supporter of causes to improve the lives of others.

The event honors young professionals who have demonstrated success in business, leadership in the community, and who are committed to fundraising for the Cystic Fibrosis Foundation. The event will be held on November 6, 2013 at 6pm, at the Turf Valley Resort and Conference Center.

The Maryland Chapter of the CFF is consistently a leader within the foundation through active volunteer participation and substantial fund-raising successes. Maryland Chapter volunteers plan, organize, and implement various fund raising projects throughout the year. The Finest Under 39 event will recognize honorees as prominent business leaders in the community, facilitate excellent networking opportunities, and promote fund raising towards helping to find a cure for Cystic Fibrosis.

“It is an incredible honor to be nominated by the CFF for this designation. The team at Proove Biosciences works hard to ensure we continue to produce industry leading research, as well as the tools that pain treatment professionals rely on daily,” stated Meshkin. “As the CEO of Proove, I understand the importance of genetic research, and will continue to support the efforts of the CFF in finding a cure for this disease.”

Cystic fibrosis is a devastating genetic disease that affects the lungs and digestive system. More than ten million Americans are symptomless carriers of the defective CF gene. Advances continue to be made in finding a cure, but help is needed now -- more than ever -- to help keep up the momentum of this life-saving research. When the Foundation began in 1955, most children with CF did not live to see their first day of elementary school. Today, the median predicted age of survival for a person with CF is in the mid-30s. This is remarkable progress, but not good enough. To learn more about CF and the CF Foundation, visit http://www.cff.org. To make a contribution to support this important research and support Brian’s fundraising effort, click here.

About Proove Biosciences
Proove Biosciences is a Personalized Pain Medicine company that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. Based in Southern California, physicians use Proove testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove Biosciences performs proprietary genetic tests in a CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).

Read the full story at http://www.prweb.com/releases/2013/9/prweb11156213.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
2. Sanomedics International Holdings, Inc. appoints new Chairman of the Board and installs new Director of Business Development.
3. James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals
4. Microvi Biotechnologies Appoints Former COO of Zenon Environmental as Chairman of Board of Directors
5. Exosome Diagnostics Names Kapil Dhingra Chairman of the Board of Directors
6. BioRestorative Therapies Announces Chairman of Its Scientific Advisory Board to Speak at Vatican
7. Life Technologies Chairman And CEO Gregory T. Lucier Named Penn State Outstanding Engineering Alumnus
8. GlycoVaxyn AG announces Addition of Gerd Zettlmeissl, as Chairman of the Board of Directors
9. Ernest Mario, Ph.D., Named Chairman of Chimerix, Inc.
10. VIASPACE Chairman and CEO Attend EUEC 2013, Giant King Grass Prominently Featured in Convention Exhibit Hall
11. California Healthcare Institute Appoints Allergan CEO Chairman of the Board, Elects New Board Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... platform specifically designed for life science researchers to analyze and interpret datasets, ... Franklin, who made a major contribution to the discovery of the double-helix ...
(Date:10/11/2017)... ... 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. ... San Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, ... government officials from around the world to address key issues in device compliance, quality ...
(Date:10/11/2017)... ... 11, 2017 , ... Disappearing forests and increased emissions are the main causes ... each year. Especially those living in larger cities are affected by air pollution related ... the most pollution-affected countries globally - decided to take action. , “I knew I ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
Breaking Biology News(10 mins):